cancer screenings | Ignite II

Personalized Risk Assessment for Early Detection of Cancer

Personalized Risk Assessment for Early Detection of Cancer

Thursday, December 21 | 9 a.m. ET | Online

Speaker: Dr. Nora Pashayan

Dr. Pashayan is a Professor of the Epidemiology of Aging and honorary Consultant in Public Health Medicine at the University of Cambridge. She is a cancer epidemiologist, a clinician with specialties in both Family Medicine and Public Health Medicine, and the Director of Training for the International Alliance for Cancer Early Detection. Dr. Pashayan’s primary research field is cancer early detection, risk stratification, and population-level screening. Her research focuses on understanding disease courses, evaluating screening strategies, and implementation of novel screening strategies.

This talk will introduce the concept of risk-stratified cancer screening and explore the essential considerations for implementation of such a screening program. Examples on integration and implementation will be drawn from the ongoing Canadian study, PERSPECTIVE I&I.

To learn more and register, visit the GGMC Educational Webinar Series page.

Please note: Registration is required for this webinar.

Duke Precision Medicine Program Forum Series

Thursday, April 13 | 12-1 p.m. ET | Online

The Duke Precision Medicine Program Forum Series features speakers from Duke and beyond working on innovative research in clinical, translational, and basic sciences.

Kevin Shah, MD
Associate Professor of Medicine (General Internal Medicine)
Duke Department of Medicine

Title: Implementation and Impact of a Risk Stratified Prostate Cancer Screening Algorithm in Duke Primary Care

Watch the recording on the Precision Medicine Forum Series website.

Leveraging Genomics to Address Health Disparities in Rare Diseases and Cancer Screenings

Thursday, February 16 | 3:30 – 4:30 p.m. ET | Online & Bethesda, MD

C. Jimmy Lin, M.D., Ph.D., MHS is the Founder and Chief Executive Officer of Rare Genomics (RG) Institute, an international non-profit founded in 2011 to enable any community to leverage cutting-edge biotechnology to advance understanding of rare diseases. Dr. Lin is also the Chief Scientific Officer at Freenome, working on early diagnostic of cancers. Prior to Freenome, he was the Chief Scientific Officer, Oncology at Natera where he led the development of new diagnostic technologies for cancer.

Before his career in private industry, Dr. Lin led the ClinOmics program at the National Cancer Institute (NIH/NCI) and was a research instructor at Washington University in St. Louis. Dr. Lin earned his MD and PhD from Johns Hopkins School of Medicine and a Master of Health Science from the Johns Hopkins Bloomberg School of Public Health, creating genome-wide maps of breast, colorectal, pancreatic, glioblastoma, medulloblastoma, and melanoma cancers, as well as mapping the genome of an anaerobic bacteria that is used as anti-tumor therapy. He is a 2016 Senior TED Fellow and a 2016 WIRED Innovation Fellow and has been featured in several media outlets, including Forbes, Bloomberg, Wall Street Journal, New York Times, Washington Post, BBC, and TIME Magazine.